

Curriculum Vitae

Vilma Petrikaite

Personal information Work experience

1. Employer: Lithuanian University of Health Sciences, Institute of Physiology and Pharmacology

- Start date: 09/2019 End date:
- Position: Professor
- Activities: Teaching and Scientific activities. Subjects: Pharmacology (lectures, seminars and practical works)
- Country: Lithuania 2. Employer: Lithuanian University of Health Sciences, Institute of Cardiology, Laboratory of Drug Targets Histopathology Start date: 09/2019
 - End date:

 - Position: Chief Researcher, Head of the Lab Activities: Research activities. Analysis of tumor microenvironment and drug transport, development of hybrid
 - constructs for cell/tissue cultivation
- Country: Lithuania
 Employer: Lithuanian University of Health Sciences
 - - Start date: 02/2019 End date:
 - Position: Head of Preclinical Research Center
 - Activities: Coordination of scientific and experimental developmental projects at the University Country: Lithuania
- 4. Employer: Lithuanian University of Health Sciences, Faculty of Pharmacy Start date: 11/2017

 - End date: 09/2019 Position: Professor
 - Activities: Teaching and scientific activities. Subjects: Drug chemistry (lectures and practical works), Drug quality (seminars, lectures), Supervisor of Practice of Drug analysis at Pharmacy • Country: Lithuania
- 5. Employer: Lithuanian University of Health Sciences, Faculty of Pharmacy Start date: 05/2012

 - End date: 11/2017 Position: Associate Professor
 - Activities: Teaching and scientific activities. Subjects: Drug chemistry (lectures and practical works), Drug quality (seminars, lectures), Supervisor of Practice of Drug analysis at Pharmacy
- Country: Lithuania
 Employer: Lithuanian University of Health Sciences, Faculty of Pharmacy
 - Start date: 05/2007 End date: 05/2012

 - Position: Assistant Professor Activities: Teaching and scientific activities. Subjects: Drug chemistry (lectures and practical works), Drug quality (seminars, lectures)
- Country: Lithuania
 Country: Lithuania
 T. Employer: Lithuanian University of Health Sciences, Faculty of Pharmacy
 - Start date: 09/2002 End date: 05/2007
 - Position: Assistant
 - Activities: Teaching and scientific activities. Subjects: Drug chemistry (lectures and practical works), Drug guality (seminars, lectures)
- Country: Lithuania
 Employer: Vilnius University
 - Start date: 11/2016
 - End date: Position: Senior Researcher
 - Activities: Research activities. Testing anticancer drugs, analysis of tumor microenvironment, drug transport in 3D
 - cell models
 - Country: Lithuania
- 9. Employer: Vilnius University
 Start date: 09/2008
 - End date: 11/2016
 - Position: Researcher
 - Activities: Research activities. Testing anticancer drugs, analysis of tumor microenvironment, drug transport in 3D
 - cell models
 - Country: Lithuania
- 10. Employer: ThermoPharma, LLC Start date: 05/2017
 - End date: 02/2019 Position: Scientist

 - Activities: Development of anticancer compounds
- Country: Lithuania
 Employer: Lithuanian Business Support Agency
 - Start date: 10/2016
 - End date: 12/2016
 - Position: Expert

- Activities: Evaluation of project proposals for business support
- Country: Lithuania
- 12. Employer: Maras, LLC Start date: 12/2015
 - End date: 02/2016
 - Position: Regulatory Affairs Manager
 - Activities: Translations and review of regulatory documents
- Country: Lithuania
 Employer: Lithuanian Society of Young Researchers
 - - Start date: 02/2013 End date: 07/2014
 - Position: Project manager
- Activities: Managing international and national projects
 Country: Lithuania
 Activities: Country: Lithuania
 Activities: Control Agency

 - - Start date: 05/2006 End date: 05/2012

 - Position: Expert of quality of medicinal preparations Activities: Evaluation of the quality part (pharmaceutical analytical results) of medicinal preparations (national, MRP
 - procedures, quality part variations)
- Country: Lithuania
 Employer: Lithuanian State Medicines Control Agency
 - - Start date: 06/2004 End date: 05/2006
 - Position: Chief specialist
 - Activities: Evaluation of the quality part (pharmaceutical analytical results) of medicinal preparations (national, MRP
 - procedures, quality part variations)
- Country: Lithuania
 Employer: Institute of Pharmacy and Pharmaceutical Marketing
- - Start date: 11/2003 End date: 04/2004
 - Position: Expert-consultant
 - Activities: Analysis of information regarding medicinal preparations Country: Lithuania
- - 17. Employer: Pharmaceutical enterprise "Aconitum" Start date: 032003
 - End date: 122004

 - Position: Provisor-Controller of Quality Activities: Quality evaluation of medicinal preparations, preparation of GMP documentation
 - Country: Lithuania

Education and training

- 1. Subject: Kaunas University of Medicine
 - Start date: 09/2002
 - End date: 09/2006 Qualification: PhD studies
 - Organisation: Doctor's degree in Pharmacy in 2007 09 26 (diploma DD No. 000150)
 - Country: Lithuania
- 2. Subject: Kaunas University of Medicine
 - Start date: 1996 End date: 2002
 - Qualification: Master studies
 - Organisation: Magister's degree in Pharmacy and professional qualification of pharmacist in 2002 (diploma KMU No.
 - 0001130)

 - Country: Lithuania
 Subject: Kaunas 51st secondary school
 - Start date: 1990
 - End date: 1996
 - Qualification: Secondary education
 - Organisation: Country: Lithuania
 - 4. Subject: Garliava 2nd secondary School
 - - Start date: 1984 End date: 1990
 - Qualification: Secondary education
 - Organisation:
 - Country: Lithuania
- 5. Subject: Garliava music school Start date: 1986
 - End date: 1993
 - Qualification: Musical education, speciality of violin
 - Organisation
 - Country: Lithuania

Additional information

Publications

ORCID: 0000_0002_4106_5535, h-index: 20 (WOS All databases) Publications: 67 original papers and reviews, 75 conference presentations, 8 textbooks. Publications from the last 5 years:

- Petrikaite V, Celia C, D'Avanzo N, Fresta M. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer (2023)100956. models. Resistance Updates 68 Drug https://doi.org/10.1016/j.drup.2023.100956 IF = 22.84
- Vilkickyte G, Petrikaite V, Marksa M, Ivanauskas L, IF = 7.68Jakstas V, Raudone L. Fractionation and Characterization of Triterpenoids from Vaccinium vitis-idaea L. Cuticular Waxes and Their Potential as Anticancer Agents. Antioxidants 2023, 12(2),

465. https://doi.org/10.3390/antiox12020465 IF = 7.68

- Braciuliene A, Janulis V, **Petrikaite V**. The Chemosensitizing Effect of Doxorubicin of Apple Extract-Enriched Triterpenic Complex on Human Colon Adenocarcinoma and Human Glioblastoma Cell Lines. Pharmaceutics. 2022, 14, 2593. https://doi.org/10.3390/pharmaceutics14122593 IF = 6.53
- Vilkickyte G, Zilius M, **Petrikaite V**, Raudone L. Proanthocyanidins from Vaccinium vitis-idaea L. Leaves: Perspectives in Wound Healing and Designing for Topical Delivery. Plants. 2022, 11, 2615. https://doi.org/10.3390/plants11192615 IF = 4.66
- Šermukšnytė A, Tumosienė I, Kantminienė K, Jonuškienė I, Petrikaitė V. The effects of 1,2,4-triazole-3-thiol derivatives bearing hydrazone moiety on cancer cell migration and the growth of melanoma, breast and pancreatic cancer spheroids. Pharmaceuticals. 2022, 15, 1026. https://doi.org/10.3390/ph15081026. IF = 5.68
- Čiužas D, Krugly E., Petrikaitė V. Fibrous 3D printed $poly(\epsilon)$ caprolactone tissue engineering scaffold for in vitro cell models. Biochemical Engineering Journal 2022. https://doi.org/10.1016/j.bej.2022.108531 IF = 4.34
- Paškevičiūtė M., Petrikaitė V. Effect of natural flavonoids to reverse P-glycoproteinrelated multidrug resistance in breast cancer cell cultures. Am J Cancer Res 2022;12(6):2526-2538; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251692/ IF = 6.17
- Sidorova M., **Petrikaite V**. Anticancer activity of selective and non-selective beta adrenoreceptor blockers against non-small cell lung cancer cell lines. Molecules 2022, 27(6), 1938; https://doi.org/10.3390/molecules27061938 IF = 4.41
- Vilkickyte G, **Petrikaite V**, Pukalskas A, Sipailiene A, Raudone L. Exploring Vaccinium vitis-idaea L. as a potential source of bioactive agents: antimicrobial, antioxidant, and anti-inflammatory activities of extracts and fractions. J Ethnopharmacol 2022 292, 115207; https://doi.org/10.1016/j.jep.2022.115207 IF = 4.27
- Mykhailenko O, Bezruk I, Ivanauskas L, **Petrikaitė V**, Georgiyants V. Application of Quality-by-Design (QbD) and Herb MaRS approach to the pharmaceutical development of anticancer crude extracts of Crocus sativus perianth. Sci. Pharm. 2022, 90(1), 19; https://doi.org/10.3390/scipharm90010019 IF = 4.1
- Karaliute I, Ramonaite R, Bernatoniene J, **Petrikaite V**, Misiunas A, Denkovskiene E, Razanskiene A, Gleba Y, Kupcinskas J, Skieceviciene J. Eradication of the Klebsiella quasipneumoniae by encapsulated klebicin KvarIa in the mice gastrointestinal tract. Gut Pathogens 2022 (in Press)
- Barbosa MAG, Xavier CPR, Pereira RF, **Petrikaitė V**, Vasconcelos MH. 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancers 2022, 14, 190. https://doi.org/10.3390/cancers14010190 IF = 6.64
- Mykhailenko O, **Petrikaite V**, Korinek M, Chang F-R, El-Shazly M, Yen C-H, Bezruk I, Chen B-H, Hsieh C-F, Lytkin D, Ivanauskas L, Georgiyants V, Hwang T-L. Pharmacological potential and chemical composition of Crocus sativus leaves extracts. Molecules 2022, 27(1), 10; https://doi.org/10.3390/molecules27010010 IF = 4.41
- Simón-Gracia L, Kiisholts K, Petrikaite V, Tobi A, Saare M, Lingasamy P, Peters M, Salumets A, Teesalu T. Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis. Nanomaterials. 2021, 11, 3257. https://doi.org/10.3390/nano11123257
 IF = 5.08
- Balandis B, Mickevicius V, **Petrikaite V**. Exploration of benzensulfonamide-bearing imidazole derivatives activity in triple-negative breast cancer and melanoma 2D and 3D cell cultures. Pharmaceuticals 2021, 14, 1158; https://doi.org/10.3390/ph14111158 IF = 5.83
- Janonienė A, Mazutis L, Matulis D, Petrikaite V. Inhibition of carbonic anhydrase IX suppresses breast cancer cell motility at the single-cell level. Int. J. Mol. Sci. 2021, 22(21), 11571; https://doi.org/10.3390/ijms222111571 IF = 5.92
- Hafeez M.N., Celia C., Petrikaite V. Challenges towards targeted drug delivery in cancer nanomedicines. Processes 2021, 9(9), 1527; https://doi.org/10.3390/pr9091527 IF = 2.85
- Žukauskas M, Grybaitė B, Jonutė P., Vaickelionienė R, Gibieža P., Vaickelionis G, Dragūnaitė B., Anusevičius K, Mickevičius V, Petrikaitė V. Synthesis and anticancer evaluation of N-aryl-β-alanine derivatives. Bioorg chem 2021, 115, 105214. doi: https://doi.org/10.1016/j.bioorg.2021.105214 IF = 5.28
- Gibieža P, Petrikaitė V. Actin dynamics during cell division and malignancy. Am J Cancer Res 2021;11(9):4050-4069. eCollection 2021 IF = 6.17

- Tumosienė I, Jonuškienė I, Kantminienė K, Mickevičius V, Petrikaitė V. Synthesis of N-substituted amino acid hydrazone-isatin derivatives, their antioxidant and anticancer activity in 2D and 3D models in vitro. Int J Mol Sci 2021, 22, 7799. https://doi.org/10.3390/ijms22157799 IF = 5.92
- Liaudanskas M., Žvikas V., **Petrikaite V**. Relationship between antioxidant and anticancer activity of series plant extracts in melanoma, glioblastoma and breast cancer cell cultures in vitro. Antioxidants 2021, 10, 1115. https://doi.org/10.3390/antiox10071115 IF = 6.31
- Mykhailenko O, Petrikaitė V, Korinek M, El-Shazly M, Chen B-H, Yen C-H, Hsien C-F, Bezruk I, Dabrišiūtė A, Ivanauskas L, Georgiyants V, Hwang T-L. Bioguided bioactive profiling and HPLC-DAD fingerprinting of Ukrainian saffron (Crocus sativus stigma): Moving from Correlation toward Causation. BMC Complementary Medicine and Therapies. 2021, 21, 203. https://doi.org/10.1186/s12906-021-03374-3 IF = 2.83
- Butkeviciute A, **Petrikaite V**, Jurgaityte V, Liaudanskas M, Janulis V. Antioxidant, antiinflammatory, and anticancer activity of apple extracts. Antioxidants. 2021, 10(7), 1098; https://doi.org/10.3390/antiox10071098 IF = 6.31
- Li W, Kai Zheng, **Petrikaite V**. Editorial: Hybrids Part B: Hybrids for Drug Delivery. Front Bioeng Biotechnol, 2021. doi: 10.3389/fbioe.2021.720714 IF = 5.48
- Daunys S., Janoniene A., Januškeviciene I., Paškeviciute M., Petrikaite V. 3D tumour Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles, Adv Exp Med Biol, 2021;1295:243-270. doi: 10.1007/978-3-030-58174-9_11 IF = 2.62
- Gibieza P., Petrikaite V. The dual functions of Rab11 and Rab35 GTPases regulation of cell division and promotion of tumorigenicity. Am J Cancer Res, 2021;11(5):1861-1872. IF = 5.18
- Bytautaite M, **Petrikaite V.** Comparative Study of Lipophilic Statin Activity in 2D and 3D in vitro Models of Human Breast Cancer Cell Lines MDA-MB-231 and MCF-7. Onco Targets Ther. 2020; 13:13201-13209. https://doi.org/10.2147/OTT.S283033 IF = 3.24
- Vilkickyte G, Raudone L, Petrikaite V. Phenolic fractions from Vaccinium vitis-idaea L. and assessment of their antioxidant and anticancer activities. Antioxidants 2020, 9, 1261; doi:10.3390/antiox9121261 IF = 5.01
- Stravinskiene D, Sliziene A, Baranauskiene L, Petrikaite V, Zvirbliene A. Inhibitory Monoclonal Antibodies and their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells. Int. J. Mol. Sci. 2020, 21(24), 9411; https://doi.org/10.3390/ijms21249411 IF = 4.56
- Mykhailenko O, Korinek M, Ivanauskas L, Bezruk I.,Myhal A, **Petrikaitė V**, El-Shazly M, Lin G-H, Yen C-H, Chen B-H, Georgiyants V, Hwan T-L. Qualitative and quantitative analysis of Ukrainian Iris species: A fresh look on their content and biological activities. *Molecules* 2020, 25, 4588; doi: <u>10.3390/molecules25194588</u> IF = 3.27
- Paškevičiūtė M., Januškevičienė I., Sakalauskienė K., Raišutis R., Petrikaite V. Evaluation of low-intensity pulsed ultrasound on doxorubicin delivery in 2D and 3D cancer cell cultures. Sci Rep 10, 16161 (2020). https://doi.org/10.1038/s41598-020-73204-y IF = 3.99
- Daunys S., **Petrikaite V**. Roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis. Biology of the Cell. 2020; doi: 10.1111/boc.201900099 IF = 3,92
- Tumosienė I, Kantminienė K, Klevinskas A, Petrikaitė V, Jonuškienė I, Mickevičius V. Antioxidant and anticancer activity of novel derivatives of 3-[(4-methoxyphenyl)amino]propanehydrazide. *Molecules* 2020, 25(13), 2980; https://doi.org/10.3390/molecules25132980. IF = 3.260
- Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, **Petrikaite V**, Assaraf YG, Passirani C. Nanomedicine to target MDR tumors. Drug Resistance Updates. 2020, 52, 100704; doi: 10.1016/j.drup.2020.100704. IF = 11.708
- Janoniene A., Petrikaite V. In search of exclusively tumour treating tools: achievements and perspectives of systems targeting CA IX. J Mol. Pharmaceutics 2020, 17, 6, 1800–1815. https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.0c00180. IF = 4.396
- Paškevičiūtė M., Petrikaitė V. Application of carbonic anhydrase inhibitors to

increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D cancer cell cultures. Am J Cancer Res. 2020; 10(6): 1761-1769. IF = 4.737

- Januskeviciene I., Petrikaite V. Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations. Life Sci 2019 Oct 24:117009. doi: 10.1016/j.lfs.2019.117009. IF = 4.525
- Daunys S., Matulis D., **Petrikaite V**. Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures. Sci Rep. 2019 Nov 7;9(1):16177. doi: 10.1038/s41598-019-52652-1. IF = 3.448
- Paškevičiūtė M., Petrikaite V. Proton pump inhibitors modulate doxorubicin and its liposomal form transport into 2D and 3D breast cancer cell cultures. Cancer management and research. 2019 Nov 21;11:9761-9769. doi: 10.2147/CMAR.S224097. eCollection 2019. IF = 3.702
- Stravinskiene D., Imbrasaite A., Petrikaite V., Matulis D., Matuliene J., Zvirbliene A. New monoclonal antibodies for a selective detection of membrane-associated and soluble forms of carbonic anhydrase IX in human cell lines and biological samples. Biomolecules. 2019, 9(8), 304; https://doi.org/10.3390/biom9080304 IF = 4.694
- Meleddu R, Petrikaite V, Distinto S, Arridu A, Angius R, Serusi L, Škarnulytė L, Endriulaitytė U, Paškevičiūtė M, Cottiglia F, Gaspari M, Taverna D, Deplano S, Fois B, Maccioni E. Investigating Anticancer Activity of Isatin/Dihydropyrazole Hybrids. ACS Medicinal Chemistry Letters. 2018. doi: 10.1021/acsmedchemlett.8b00596 IF = 3.95
- Paskeviciute M., **Petrikaite V**. Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades. Drug Deliv and Transl Res. 2018. doi: 10.1007/s13346-018-0584-7. IF = 3.395
- Ceponyte U., Paskeviciute M., Petrikaite V. Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures. Cancer Management and Research. 2018:10;1543-1551; doi: https://doi.org/10.2147/CMAR.S163747 IF = 3.702

Ρ	roj	ec	ts	

2022	Supervisor of the project according to the American Dialogue program
	"Expanding collaboration links between the Lithuanian and US biomedical
	scientists", funded according to the Baltic-American Freedom Foundation
	(BAFF) program.

- 2021-2022 Supervisor of the project "Hybrid 3D Tissue Engineering Scaffolds for Cell Cultivation and Cytotoxicity Testing in vitro", funded according to the measure of the Agency for Science, Innovation, and Technology "Technological Development Project Financing Facility".
- 2021-2022 Supervising the student's research project "Evaluation of sunitinib analogs effect in triple-negative breast cancer 3D cell cultures", funded according to Measure 09.3.3-LMT-K-712 of the Operational Programme for the EU Fund.
- 2021-2023 Supervising a PostDoc project 09.3.3-LMT-K-712-19-0011 "In vitro studies of tumorigenicity of Rab protein-regulated tumor cells", funded by the European Social Fund under the program No. 09.3.3-LMT-K-712-23 "Development of Competencies of Scientists, other Researchers, and Students through Practical Research Activities" measure.
- 2021-2023 Supervising the Mobility project LAS-21-04 "Effect of flavonolignan derivatives in multi-drug resistant cancers", funded according to the bilateral

	program between Lithuania and the Czech Republic.
2021	Leader of the National inter-institutional project "Evaluation of technological properties of enzymatically synthesized fructooligosaccharides and in vitro study of their potential application for combination chemotherapy"
2021	Supervising the student's summer research practice "Evaluation of sunitinib analogs effect on triple-negative breast cancer cell migration in vitro in hypoxia conditions", funded according to the Measure 09.3.3-LMT-K-712 of the Operational Programme for the EU Fund.
2020-2022	Supervising a PostDoc project 09.3.3-LMT-K-712-19-0181 "Hybrid 3D Tissue Engineering Scaffolds for Research in vitro", funded by the European Social Fund under the program No. 09.3.3-LMT-K-712-23 "Development of Competencies of Scientists, other Researchers, and Students through Practical Research Activities" measure.
2020-2021	Supervising the student's summer research practice "Evaluation of sunitinib analogs effect on colon cancer cell migration in vitro", funded according to Measure 09.3.3-LMT-K-712 of the Operational Programme for the EU Fund.
Since 2020	Participation in COST project No. CA19138 "Lobular breast cancer:
Discovery Scienc	e, Translational Goals, Clinical impact (MC member)
2019-2020	Supervising school pupils' research and giving lectures according to the interdisciplinary training program for gifted pupils "Gifted pupils".
2019	Supervising the student's summer research practice "Evaluation of beta adrenoblockers effect on breast cancer cell migration and invasion in vitro", funded according to Measure 09.3.3-LMT-K-712 of the Operational Programme for the EU Fund
2019 L for efficiency of c	eader of the National inter-institutional project "Influence of pulsed ultrasound compound penetration into cancer cell 2D and 3D cultures"
2018	Supervising the student's summer research practice "Evaluation of antimetastatic activity in vitro of new kinase inhibitors", funded according to Measure 09.3.3-LMT-K-712 of the Operational Programme for the EU Fund
2018-2022	Participation in COST project No. CA17104 "New diagnostic and therapeutic
tools against mult 2018-2021 delivery"	idrug-resistant tumors" (STRATAGEM) (MC member) Participation in National project "Application of exosomes for targeted drug
2017	Leader of the National inter-institutional project "Influence of ultrasound for
the efficiency	
	of anticancer drugs in 3D cultures formed from different types of cells"
2016-2019	Participation in COST project No. CM1406 "Epigenetic chemical biology (EPICHEM) (MC substitute member)
2015-2017	Participation in National scientific program SEN-15014 "Healthy Aging"
2012 -2015	Participation in Global Grant VP1-3.1-ŠMM-07-K-009 "Synthesis of
selective carbonic	e anhydrase inhibitors and their anticancer activity"
2013-2014	Project leader "Strengthening institutional abilities of Lithuanian Society of

Young Researchers".

2012-2013Participation in National scientific program LIG-09/2010 "Chronic non-
infectious diseases"2010-2011Participation in National scientific program LIG-16/2010 "Chronic non-
infectious diseases"

2010-2014 Participation in COST project No. TD0905 "Epigenetics: from bench to bedside" (MC member)

2009-2013 Participation in COST project No. TD0804 "Chemical biology with natural products" (MC substitute member)

Memberships Participation in Committees, Programs and Work Groups

Since 2022 Member of the Advisory Group of the BAFF Alumni Mentorship program

2021-2022 Mentor in the BAFF Alumni Mentorship program

Since 2018 Member of the PhD Committee for the Pharmaceutical field at LSMU

2018-2021 Member of the Board of the Bioethics Center at LSMU

2017-2019 Member of Pharmacy Study Programme Committee at LSMU

2017-2019 Chairperson of the Qualification Committee for Master Thesis at LSMU Faculty of Pharmacy

2013-2017 Member of the Qualification Committee for Master Thesis at LSMU Faculty of Pharmacy

2013-2015 Participation in organization of Goethe-Institut contest "German language for curious pupils"

2013-2014 Main editor of the monthly journal "Odė mokslui" (<u>http://www.ljms.lt/ode-mokslui</u>)

2013 Participation in UNESCO workgroup preparing Lithuanian policy paper on Open Access to Scientific Results (organization of seminars and discussions)

2012-2013 Participation in the Steering Committee of the program "Research and Development" approved by the Ministery of Science and Education

2010-2012 Organization of the annual national contest "Best Master Thesis" (project leader)

2006-2014 Organization of the annual national contest "Best PhD Thesis" (project leader)

2005-2006 Member of EMEA (European Medicines Evaluation Agency) workgroup *"Quality Review of documents"* (QRD) (delegated from SMCA)

Internships

2022, June	Università degli Studi "Gabriele d'Annunzio", Faculty of Pharmacy,
Italy	
2022, March	Universidad Complutense de Madrid, Faculty of Pharmacy, Spain
2021, November	University of Tartu, Institute of Biomedicine and Translational
Medicine, Estonia	
2021, November	Cagliari University, Faculty of Pharmacy, Italy
2021, February-Mar	ch University of Tartu, Institute of Biomedicine and Translational

Medicine, Estonia **2020, January** Università degli Studi "Gabriele d'Annunzio", Faculty of Pharmacy, Italy

2019, November Yeditepe University, Faculty of Pharmacy, Turkey

2019, July-August Pharmaceutical Nanotechnology and Chemical Microsystem Unit, University of Helsinki, Finland

2018, January-April The Department of Cell and Developmental Biology, Colorado University School of Medicine, Denver, USA

2017, April-June Pharmaceutical Nanotechnology and Chemical Microsystem Unit, University of Helsinki, Finland

2016, July-August Department of Cell and Developmental Biology, Colorado University School of Medicine, Denver, USA

2016, March Department of Cell and Developmental Biology, Colorado University School of Medicine, Denver, USA

2015, August The Division of Developmental Biology, Cincinnati Children's Hospital, Cincinnati, USA

2014, September- The Department of Nanomedicine, Houston Methodist Research Institute, Houston, USA

2015, August Postdoctoral scholarship

2013, October Institute of Biomedical Technology, University of Tampere, Tampere, Finland

2012, June-July Cancer Epigenetics Group, Bellvitge Biomedical Research Centre (IDIBELL), Barcelona, Spain

2009-2011The Department of Biothermodynamics and Drug Design, VilniusUniversity

Scholarships, Awards, and Recognition

2020 My PhD student Migle Paskeviciute was awarded as the best PhD student at LSMU in 2019-2020

2020 Grant from the Research Council of Lithuania for a research scholarship in Tartu University, Estonia

2019 Grant from the Research Council of Lithuania for a research scholarship in Helsinki University, Finland

2019 Grant from the Research Council of Lithuania to attend "ESMO Congress 2019", Barcelona, Spain

2018 My PhD student Migle Paskeviciute was awarded as the best PhD student at LSMU in 2017-2018

2018 The best young researcher at LSMU, the 3rd place

2017 Grant from the Research Council of Lithuania to attend conference "3D Tissue Models 2017", USA

2016 The LSMU Open Science Foundation award for a research scholarship in Colorado University, USA

2015 Grant from the Research Council of Lithuania for a research scholarship in Colorado University, USA

2014 The Baltic-American Freedom Foundation (BAFF) award for a research scholarship in the USA

2014 Grant from the Research Council of Lithuania to attend "13th Annual World Pharma Congress", USA

2012 Short-term scientific mission in Bellvitge Biomedical Research Institute (IDIBELL), Barcelona (funding from COST action TD0905)

2012 Grant from the Research Council of Lithuania to attend "6th International Conference on the Hsp90 Chaperone Machine", Les Diablerets, Switzerland

2012 Grant from the LSMU Open Science Foundation to attend International Conference "Protein Targets: Discovery of Bioactive Compounds", Saragosa, Spain

2010 Award from Lithuanian Minister of Science and Education, and from Kaunas Mayor for the excellent preparation of school pupils for the 22nd EU Contest for Young Scientists

2005 Scholarship from The European Fellowship for Pharmacists for the professionalism and interest in clinical pharmacy

2005 Grant from the LSMU Open Science Foundation to attend "Pharmacy World and Science, 5th Spring Conference on Clinical Pharmacy", Stockholm, Sweden

2005 Memorial scholarship from Prof. Remigijus Zaliunas, Rector of Kaunas University of Medicine, for the excellent academical achievements

2004 Lithuanian State Science and Studies Foundation award for PhD studies

2001 Memorial scholarship from L.Stašionienė Foundation (Australia), for the excellent achievements

Participation as guest editor of scientific journals

- "Biomolecules" special issue "In Vitro Development of Targeted Drugs and Nanoparticles"
 - (https://www.mdpi.com/journal/biomolecules/special issues/In Vitro Development
- "Processes" special issue "Application of Nanoparticles in Cancer Therapy" (<u>https://www.mdpi.com/journal/processes/special issues/Nanoparticles Cancer Therapy</u>)
- "Frontiers in Bioengineering and Biotechnology" special topic "Hybrids Part B: Hybrids for Drug Delivery" (<u>https://www.frontiersin.org/research-topics/13593/hybrids-part-b-hybrids-for-drug-delivery</u>)

Memberships

Since 2015	Alumni of the Baltic American Freedom Foundation (BAFF)
Since 2015	Member of the Council of Alumni of LSMU Faculty of Pharmacy
Since 2004	Participation in the activities of the Lithuanian Society of Young Researchers
(LSYR):	
since 2015	An honored member of LSYR
2013-2014	Vice-president of LSYR
2011-2012,	President of LSYR
2008-2010	
2005-2008	Member of the Council of LSYR
2005-2008	Member of the European Society of Clinical Pharmacy (ESCP)
2005-2006	Secretary of the PhD council of KMU
Since 2004	Member of the Lithuanian Scientific Society
2002-2022	Participation in the activities of the Lithuanian Society of Pharmacy (LFS):
since 2002	A member of LFS
since 2019	Board member of LFS
2019-2020	Vice-president of LFS
2020-2021	President of LFS

Other Relevant

Information